Abstract Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). Methods Florbetapir PET was acquired in 184 subjects (45 AD patients,… Read More
SCOTTSDALE, Ariz. — Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen"… Read More
Ron Korn, M.D. of Imaging Endpoints was recently asked about his team’s work toward the integration of imagery into drug discovery and development. While full integration is a thing of the future, the use of imagery in drug discovery and development can lend significant insights into the biology and efficacy of a drug.
Abstract Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS… Read More
To read more click here Weiss G.J. and Korn R.L. “Interpretation of PET Scans: Do Not Take SUVs at Face Value.” J Thor Onc., 7(12): 1744-45, (2012).
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
